Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › Abbott Gets CLIA Waiver for Reformulated Rapid Influenza Test With Diagnostic Reader

Abbott Gets CLIA Waiver for Reformulated Rapid Influenza Test With Diagnostic Reader

Feb 27, 2019
|
staff reporter

NEW YORK (360Dx) – Abbott said today that the US Food and Drug Administration has granted a CLIA waiver for use of its reformulated rapid influenza diagnostic test, BinaxNOW Influenza A & B Card 2, with the firm's Digival diagnostic reader for the rapid detection of influenza virus.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Infectious Disease

  1. FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results

    Premium

  2. DiaSorin Receives CE Mark to Use Saliva Samples With COVID-19 Test

  3. Vendors Search for New Applications After SARS-CoV-2 Serology Fails to Fulfill Early Hype

    Premium

  4. Bio-Techne, Qiagen Expand Partnership on Exosome Technology

  5. Roche Gets FDA Emergency Use Authorization for Rapid Coronavirus, Flu Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.